STOCK TITAN

Merck’s Richard R. DeLuca sells 58,185 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Merck & Co., Inc. executive Richard R. DeLuca, executive vice president and president of Merck Animal Health, exercised options for 58,185 common shares on November 12, 2026, at an adjusted exercise price of $77.62 per share, then sold 58,185 shares at a weighted average of $148.0085 per share. The sale occurred in multiple transactions priced from $148.0000 to $148.0800. His reported option position after the transaction was zero; he reported 1,335.9494 shares indirectly through a 401(k).

Insider DeLuca Richard R.
Role EVP&Pres, Merck Animal Heallth
Sold 58,185 shs ($8.61M)
Approx. gross sale proceeds $8.61M
Approx. exercise cost $4.52M
Approx. pre-tax spread $4.10M
Share of Position Sold 34.0%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3, F4 58,185 $0.00 $0.00
Exercise Common Stock F1 58,185 $77.62 $4.52M
Sale Common Stock F2 58,185 $148.0085 $8.61M
Holding Common Stock - 401(k) Plan F1 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 112,955.434 shares (Direct); Common Stock - 401(k) Plan — 1,335.9494 shares (Indirect, By 401(k))
Holdings Before and After: Stock Option (Right to Buy), 58,185 to 0 options (Direct); Common Stock, 112,955.434 to 112,955.434 shares (Direct)
Footnotes (4)
  1. F1. Holdings include shares acquired in dividend reinvestment transactions.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.0000 to $148.0800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  3. F3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
  4. F4. The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
Shares acquired upon option exercise 58,185 shares November 12, 2026
Adjusted exercise price $77.62 per share Options exercised November 12, 2026
Shares sold 58,185 shares November 12, 2026
Weighted average sale price $148.0085 per share Sale on November 12, 2026
Individual sale price range $148.0000–$148.0800 per share Multiple transactions on November 12, 2026
Reported option position after transaction 0 shares Following the November 12, 2026 transaction
Indirect 401(k) holdings 1,335.9494 shares Reported for November 12, 2026
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
exercise price financial
"Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
exercisable financial
"The option vested and became exercisable in three equal installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MRK shares did Richard R. DeLuca sell, and at what price?

Richard R. DeLuca, executive vice president and president of Merck Animal Health, sold 58,185 shares on November 12, 2026, at a weighted average price of $148.0085 per share. Individual sale prices ranged from $148.0000 to $148.0800. No Rule 10b5-1 plan is reported.

When did Richard R. DeLuca’s MRK options vest and expire?

The options vested and became exercisable in three equal installments on May 3, 2020, May 3, 2021, and May 3, 2022. Their stated expiration date was May 2, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeLuca Richard R.

(Last)(First)(Middle)
MERCK & CO., INC.
126 EAST LINCOLN AVENUE

(Street)
RAHWAY NEW JERSEY 07065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP&Pres, Merck Animal Heallth
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026M58,185A$77.62171,140.434(1)D
Common Stock11/12/2026S58,185D$148.0085(2)112,955.434D
Common Stock - 401(k) Plan1,335.9494(1)IBy 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$77.62(3)11/12/2026M58,18505/03/2020(4)05/02/2029Common Stock58,185$00D
Explanation of Responses:
1. Holdings include shares acquired in dividend reinvestment transactions.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.0000 to $148.0800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
4. The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading